Trial Profile
A Phase Ib Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Jul 2022
Price :
$35
*
At a glance
- Drugs Benmelstobart (Primary) ; Catequentinib (Primary)
- Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 07 Jun 2022 Status changed from recruiting to completed as per results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2022 Results of exploratory analysis of the TQB2450-Ib-07 trial presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology.